Generated by AI
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors. Its core platform uses non-genetically engineered tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of creating broader anti-cancer activity. The company’s current pipeline includes product candidates such as MT-601, being studied in lymphoma and pancreatic cancer, and MT-401-OTS, being evaluated in acute myeloid leukemia and myelodysplastic syndromes. Marker Therapeutics also explores peptide-based vaccine approaches as part of its cancer treatment portfolio. Headquartered in Houston, Texas, the company operates in the biotechnology sector and serves the specialized area of cell therapy research and development, where its work supports the advancement of next-generation treatments for difficult-to-treat malignancies.
Website2450 Holcombe Blvd
Houston, TX, 77021
United States
The latest articles about MRKR.
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Summary of Jan 8's posts. Generated by AI.
Summary of Jan 8's posts. Generated by AI.
Summary of Aug 26's posts. Generated by AI.
Summary of Jan 8's posts. Generated by AI.
Investors talking about MRKR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.